Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 6/20 | 0.47 |
| ▸ | RAD51 | Q06609 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4643669 | 0.85 | GSK3B (0.72) | GSK3BMEN1KMT2AXDHSMN1; SMN2 | |
| SCHEMBL5377975 | 0.84 | GSK3B (1.00) | GSK3BXDHSMN1; SMN2 | |
| SCHEMBL28132422 | 0.78 | GSK3B (0.70) | GSK3BMEN1LMNAKMT2AXDH | |
| SCHEMBL5380569 | 0.77 | GSK3B (0.73) | GSK3BKMT2ASMN1; SMN2GAAKDM4E | |
| SCHEMBL10684112 | 0.77 | ADORA2A (0.61) | GSK3BMEN1KMT2AXDHKDM4E | |
| SCHEMBL5400045 | 0.76 | GSK3B (0.69) | GSK3BKMT2AXDHSMN1; SMN2KDM4E | |
| SCHEMBL18097860 | 0.74 | PDE2A (0.47) | GSK3B | |
| SCHEMBL12264964 | 0.71 | MEN1 (0.55) | MEN1LMNAKMT2ARAD51SMN1; SMN2 | |
| SCHEMBL13231715 | 0.71 | MEN1 (0.61) | MEN1LMNAKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL5386996 | 0.71 | GSK3B (0.78) | GSK3BMEN1KMT2AXDHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008110891-A2 | NEW HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED, (IN) | 2008-09-18 | — | — | WO | disclosed |
| US-20080221103-A1 | New heterocyclic compounds | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
| US-20080221103-A1 | New heterocyclic compounds | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
| US-20080221103-A1 | New heterocyclic compounds | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221103-A1 | New heterocyclic compounds | LOXL4, CXCR4, LTC4S | GSK3B 85/4885MEN1 1470/4885LMNA 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.